This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $481,617 to Louisiana State University Health Sciences Center New Orleans to support research on the use of elovanoids (EVLs), stereospecific fatty acid derivatives, to protect the stroke penumbra and limit expansion of the ischemic core after an ischemic stroke event.
The key objectives of this 5-year project are to: 1) evaluate how EVL precursor fatty acids 32:6n-3 and 34:6n-3 activate EVL biosynthesis and protect the ischemic penumbra in rat models of stroke; and 2) define the molecular mechanisms by which EVLs sustain penumbra integrity and limit core expansion, including modulation of inflammation, transcriptional changes in specific cell types, and restoration of blood-brain barrier integrity. The project will leverage advanced techniques like single-nuclei multiomics, spatially resolved transcriptomics, and proteomic analysis to elucidate the neuroprotective effects of EVLs. The findings have the potential to lead to the development of novel stroke therapies to improve outcomes for patients.
Generated 3/4/25, 7:02 AM